(Reuters) - Galena Biopharma said its breast cancer vaccine received a patent granting it exclusivity until 2028, sending its shares up as much as 35 percent.
The vaccine, NeuVax, gives immunity against the relapse of breast cancer in patients who have low-to-intermediate levels of HER2 -- a protein that can affect the growth of cancer cells.
NeuVax is being tested in a late-stage study under a special protocol assessment agreement with the U.S. Food and Drug Administration.
Read the full story here:
http://www.reuters.com
